Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06979531 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity
A Phase 2 study of Primary Sjögren's Syndrome, sponsored by Immunovant Sciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
- 20
- Study locations
NCT06979531 is a Phase 2 study of Primary Sjögren's Syndrome that is actively recruiting participants, run by Immunovant Sciences. The registered enrollment target is 180 participants. The trial reports 20 study locations across 8 states.
The verdict
NCT06979531, a Phase 2 study of Primary Sjögren's Syndrome, is actively recruiting participants, sponsored by Immunovant Sciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2b, multicenter, randomized, double-blinded, placebo-controlled study to assess the efficacy and safety of IMVT-1402 in adult participants with moderate to severe systemic primary Sjogren's disease (SjD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG IMVT-1402
Study Locations (20)
California
- Site Number - 1027 - Covina
- Site Number - 1007 - El Cajon
- Site Number - 1016 - Menifee
- Site Number - 1029 - Thousand Oaks
- Site Number - 1026 - Upland
Florida
- Site Number - 1018 - Hollywood
- Site Number - 1021 - Jupiter
- Site Number - 1002 - Miami
- Site Number - 1004 - Tamarac
- Site Number - 1025 - Tampa
Illinois
- Site Number - 1012 - Chicago
- Site Number - 1033 - Orland Park
Louisiana
- Site Number - 1030 - Lake Charles
- Site Number - 1028 - New Orleans
New York
- Site Number - 1032 - Canton
- Site Number - 1006 - Mineola
Tennessee
- Site Number - 1015 - Jackson
- Site Number - 1000 - Memphis
Colorado
- Site Number - 1014 - Fort Collins
Pennsylvania
- Site Number - 1013 - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2025-06-30 |
| Est. Completion | 2029-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06979531
The ClinicalTrials.gov registry entry for NCT06979531 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Immunovant Sciences, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Sjögren's Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06979531 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT06979531 about?
NCT06979531 is a clinical study titled "Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity". This is a Phase 2b, multicenter, randomized, double-blinded, placebo-controlled study to assess the efficacy and safety of IMVT-1402 in adult participants with moderate to severe systemic primary Sjogren's disease (SjD).
What is the current status of trial NCT06979531?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2025-06-30. Estimated completion is 2029-07.
What conditions does trial NCT06979531 study?
This clinical trial studies the following conditions: Primary Sjögren's Syndrome.
What interventions are being tested in trial NCT06979531?
The interventions under investigation include: Placebo (DRUG), IMVT-1402 (DRUG).
Who is sponsoring clinical trial NCT06979531?
This trial is sponsored by Immunovant Sciences, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06979531 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Sjögren's Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis
COMPLETED · Phase 2
-
A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.